Vir Biotechnology Stock Today
| VIR Stock | USD 7.96 0.10 1.27% |
Performance2 of 100
| Odds Of DistressLess than 30
|
Vir Biotechnology is selling at 7.96 as of the 1st of December 2024; that is 1.27 percent increase since the beginning of the trading day. The stock's lowest day price was 7.66. Vir Biotechnology has about a 30 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Vir Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of December 2022 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2019 | Category Healthcare | Classification Health Care |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 137.72 M outstanding shares of which 5.51 M shares are at this time shorted by investors with about 4.36 days to cover. More on Vir Biotechnology
Moving against Vir Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vir Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | MBA MSc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Experion Holdings Ltd, VIR] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVir Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vir Biotechnology's financial leverage. It provides some insight into what part of Vir Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vir Biotechnology (VIR) is traded on NASDAQ Exchange in USA. It is located in 1800 Owens Street, San Francisco, CA, United States, 94158 and employs 587 people. Vir Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.1 B. Vir Biotechnology runs under Biotechnology sector within Health Care industry. The entity has 137.72 M outstanding shares of which 5.51 M shares are at this time shorted by investors with about 4.36 days to cover.
Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vir Biotechnology Probability Of Bankruptcy
Ownership AllocationVir Biotechnology shows a total of 137.72 Million outstanding shares. The majority of Vir Biotechnology outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vir Biotechnology to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vir Biotechnology. Please pay attention to any change in the institutional holdings of Vir Biotechnology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vir Ownership Details
Vir Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | |
| Renaissance Technologies Corp | 2024-09-30 | 1.2 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | |
| Jefferies Financial Group Inc | 2024-09-30 | 1.1 M | |
| Voloridge Investment Management, Llc | 2024-09-30 | 975.3 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 930.7 K | |
| Northern Trust Corp | 2024-09-30 | 878.9 K | |
| Bank Of America Corp | 2024-06-30 | 851.8 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 813.3 K | |
| Sb Investment Advisers (uk) Ltd | 2024-09-30 | 16.7 M | |
| Blackrock Inc | 2024-06-30 | 16.4 M |
Vir Biotechnology Historical Income Statement
Vir Stock Against Markets
Vir Biotechnology Corporate Management
| Vanina JD | General VP | Profile | |
| Klaus Frueh | CoFounder Advisor | Profile | |
| Lawrence MD | CoFounder Advisor | Profile | |
| Johanna FriedlNaderer | Ex COO | Profile | |
| George Scangos | CEO Pres | Profile | |
| Louis MD | CoFounder Advisor | Profile |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.